LKFT NASDAQ Week ended 24 Jul 2026

Weekly Investor Report

Lakefront Biotherapeutics NV · Healthcare · Biotechnology

Open interactive chart View report data Download investor PDF
Latest close 27.84 USD
-7.2% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is -8.9% below the Trend Line and sits at 12.5% of its 52-week range. The latest completed week returned -7.2%, after a -5.6% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth ranks strongly; valuation is inexpensive relative to peers. Options positioning is mixed with 24/100 conviction, while the latest news-sentiment score is 49/100. Near-term considerations: volume confirmation is below normal; earnings are due in 11d.

Setup score 36 out of 100
Latest Close 27.84 USD 24 Jul 2026
1W Return -7.2% latest completed week
4W Return -5.6% short-term follow-through
12W Return -0.6% quarterly tape
Trend Breadth 57.7% 30 of 52 weeks active
Volume Ratio 0.8x vs 13-week average
What is working
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is weak, so confirmation is not yet broad enough.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -7.2% Latest completed week; four-week move -5.6%. Indicator stack 32/87 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Options pressure Mixed 24/100 conviction; expected move 8.1%. News sentiment 49/100 30 relevant articles in the latest sentiment read. Event risk 11d Next report is scheduled for 10 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -8.9% below the Trend Line and sits at 12.5% of its 52-week range. The latest completed week returned -7.2%, after a -5.6% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.8x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
30 Jan 6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.2012-week average 0.09

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure4/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.20Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -5.6% over four weeks, -0.6% over 12 weeks, and -14.7% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W-7.2%
4W-5.6%
12W-0.6%
26W-19.1%
52W-14.7%
Active trend streak0 weeks
Active weeks in one year30
Trend breadth57.7%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.52Latest activity-pressure read.
Pressure change339.8%Four-week change in activity pressure.
Leadership-19.34Latest relative-leadership reading.
RS change-2.3%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth ranks strongly; valuation is inexpensive relative to peers.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Dec 2025 Field coverage 94% Model confidence 90%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength86/100Blend of value, momentum, and quality. Underlying universe rank 15; rank 1 is best.
Value93/100Relative valuation strength. Underlying universe rank 8; rank 1 is best.
Quality78/100Profitability and accounting quality. Underlying universe rank 23; rank 1 is best.
Momentum19/100Medium-term price momentum. Underlying universe rank 82; rank 1 is best.
Growth99/100Revenue and earnings growth. Underlying universe rank 2; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Value-quality framework90/100Value and quality alignment from the Sharemaestro SVQF framework.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
3.7x
Price divided by trailing earnings.
Price / sales
1.7x
Market value relative to trailing revenue.
EV / EBITDA
3.7x
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-16.6%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
98.0%
Gross profit retained from each unit of revenue.
Operating margin
57.1%
Operating profit retained from revenue.
Free-cash-flow margin
-28.1%
Free cash flow generated from revenue.
Return on invested capital
14.0%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
303.5%
Latest one-year revenue growth.
EPS growth
333.1%
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
7/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
0.0%
Net share repurchases relative to market value.
Shareholder yield
0.0%
Dividend yield plus net buyback yield.
Net debt / EBITDA
-0.1x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningMixed

LKFT shows mixed options pressure with a 24/100 conviction score, put-call volume ratio of n/a, expected move of 8.1%, and Sharemaestro trend signal inactive.

Conviction24/100
Expected move8.1%
Put/call volume
Pressure6
Speculation0
Volatility55
Trend agreement63
Open options detail
Insider activity-

No recent insider transactions are stored for this company.

News sentiment49/100

Weighted news tone is neutral across 30 relevant articles.

2 positive · 25 neutral · 3 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings11dNext report is scheduled for 10 Aug 2026; event risk rises as the date approaches.
Options expected move8.1%Nearest-chain priced movement where available.
52-week drawdown-26.3%Distance below the 52-week high.
13-week volatility3.3%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher10 of 2616 weeks finished lower.
Best week+4.2%Week of 26 Jun.
Worst week-9.6%Week of 27 Mar.
Latest week-7.2%Week of 24 Jul.

Shape of recent returns

Strong gains1
Modest gains9
Flat weeks0
Modest losses13
Sharp losses3
Recent vol3.3%13-week weekly-return volatility.
Base vol3.7%52-week weekly-return volatility.
Up/down split23/29Count of positive and negative weeks in the 52-week window.
Average skew2.7% / -2.6%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape37/100

Trend, activity pressure, participation, and risk combine to a 37/100 tape read.

 Indicator analysis19/100

Latest 12-week confirmation: trend 0/12, activity pressure 4/12, relative leadership 0/12.

Activity pressure 0.20; No reversal markers Factors70/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 44; Small Cap Core rank 14 SVQF90/100

Value and quality alignment from the Sharemaestro SVQF framework.

Composite rank 73.5 of 726 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options46/100

LKFT shows mixed options pressure with a 24/100 conviction score, put-call volume ratio of n/a, expected move of 8.1%, and Sharemaestro trend signal inactive.

Mixed · Options-market disagreement · Expected move 8.1% Sentiment49/100

Weighted news tone is neutral across 30 relevant articles.

Lakefront Biotherapeutics (LKFT) repurchases 95,670 shares in July 2026 Insiders50/100

No recent insider transaction evidence is stored.

 Earnings11d

Next report is scheduled for 10 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
24 Jul 202627.84 USD-7.2%30.55 USD30.87 USD0.52-19.34667.9KOff
17 Jul 202630.01 USD-0.9%30.72 USD30.96 USD0.57-15.001.1MOff
10 Jul 202630.27 USD-0.4%30.80 USD31.04 USD0.27-18.22612.4KOff
3 Jul 202630.39 USD3.1%30.85 USD31.12 USD0.09-16.82741.8KOff
26 Jun 202629.48 USD4.2%30.89 USD31.18 USD-0.22-18.90683.8KOff
19 Jun 202628.30 USD-2.1%30.95 USD31.26 USD-0.54-25.91868.2KOff
12 Jun 202628.90 USD3.1%31.03 USD31.34 USD-0.76-22.73951.4KOff
5 Jun 202628.02 USD-1.2%31.11 USD31.42 USD-0.97-23.761.2MOff
29 May 202628.35 USD3.1%31.23 USD31.52 USD-1.08-26.69436.9KOff
22 May 202627.49 USD1.6%31.34 USD31.60 USD-1.09-27.31853.7KOff
15 May 202627.05 USD-5.4%31.49 USD31.70 USD-1.14-28.09962.6KOff
8 May 202628.59 USD2.1%31.74 USD31.81 USD-1.17-24.66854.0KOff
1 May 202628.00 USD-2.1%31.92 USD31.89 USD-1.26-22.48801.2KOff
24 Apr 202628.60 USD-2.3%32.24 USD31.98 USD-1.22-20.02540.1KOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.